PRASAD SUYASH (CMO and Head of R&D) sold 8.4% of their position (50.14K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $183.1K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 7/1/2022ACC: 0001209191-22-040356
Officer· CMO and Head of R&D
Since Sep 2020
-50.14K
Net shares
Net seller
$183.1K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
50.14K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−12.32K
Price / share
$3.81
Trade value
$46.95K
% of position
2.1%
6/29/2022
593.59K→581.26K
Common Stock
Direct
Shares
−13.89K
Price / share
$3.72
Trade value
$51.68K
% of position
2.4%
6/30/2022
581.26K→567.37K
Common Stock
Direct
Shares
−23.92K
Price / share
$3.53
Trade value
$84.45K
% of position
4.2%
7/1/2022
567.37K→543.45K
Total
Net shares
−50.14K
Net value
-$183.08K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/29/2022 | S · Sale | −12.32K | $3.81 | $46.95K | 2.1% | 593.59K | 581.26K |
| Common Stock Direct | 6/30/2022 | S · Sale | −13.89K | $3.72 | $51.68K | 2.4% | 581.26K | 567.37K |
| Common Stock Direct | 7/1/2022 | S · Sale | −23.92K | $3.53 | $84.45K | 4.2% | 567.37K | 543.45K |
| Total | −50.14K | -$183.08K | ||||||
Derivative Transactions0
No derivative transactions reported